Thursday, December 15, 2005

Oncotype DX Changes Treatment Decisions in One Quarter of Breast Cancer Patients

Cancer Consultants Oncology Resource Center
Researchers at the New York University School of Medicine and the US Oncology Research Network recently reported use of the Oncotype DX™ test to predict risk of breast cancer recurrence altered treatment decisions in 25% of patients with node-negative, estrogen receptor-positive breast cancer. These results were recently presented at the 28th annual San Antonio Breast Cancer Symposium. Oncotype DX is a test indicated for patients with newly diagnosed stage I or II, node-negative, estrogen receptor-positive breast cancer who will be treated with tamoxifen. The test evaluates a panel of 21 genes to predict a patient’s 10-year risk of cancer recurrence. The test classifies patients as being at high, intermediate, or low risk of recurrence based on a Recurrence Score. Related News: Oncotype DX™ Test May Predict Outcome for Some Breast Cancer Patients (6/28/05)


Post a Comment

<< Home

/* WebRing Code */